NASDAQ:LIVN - LivaNova Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $87.50
  • Forecasted Upside: 4.08 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.82 (2.21%)

This chart shows the closing price for LIVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LivaNova Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LIVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LIVN

Analyst Price Target is $87.50
▲ +4.08% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for LivaNova in the last 3 months. The average price target is $87.50, with a high forecast of $100.00 and a low forecast of $68.00. The average price target represents a 4.08% upside from the last price of $84.07.

This chart shows the closing price for LIVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in LivaNova. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2021Needham & Company LLCReiterated RatingHoldLow
6/1/2021Piper SandlerLower Price TargetOverweight$99.00 ➝ $98.00High
4/29/2021Robert W. BairdBoost Price TargetOutperform$85.00 ➝ $100.00Low
4/28/2021Piper SandlerBoost Price Target$92.00 ➝ $99.00Low
4/13/2021Piper SandlerBoost Price TargetOverweight$81.00 ➝ $92.00Low
3/9/2021Berenberg BankReiterated RatingBuy ➝ Hold$84.00Medium
3/4/2021Needham & Company LLCReiterated RatingHoldLow
3/3/2021Berenberg BankDowngradeBuy ➝ Hold$84.00High
2/24/2021Piper SandlerBoost Price TargetOverweight$73.00 ➝ $81.00High
1/12/2021Piper SandlerBoost Price TargetOverweight$70.00 ➝ $73.00Medium
1/5/2021Needham & Company LLCDowngradeBuy ➝ HoldN/A
12/15/2020Piper SandlerBoost Price TargetOverweight$63.00 ➝ $70.00High
10/29/2020Piper SandlerBoost Price TargetOverweight$60.00 ➝ $63.00High
10/21/2020Robert W. BairdBoost Price TargetOutperform$55.00 ➝ $65.00Medium
9/1/2020Robert W. BairdInitiated CoverageOutperform$55.00Low
7/29/2020Piper SandlerLower Price TargetPositive ➝ Overweight$65.00 ➝ $60.00Low
7/29/2020Needham & Company LLCLower Price TargetBuy$76.00 ➝ $68.00High
6/26/2020Needham & Company LLCLower Price TargetBuy$84.00 ➝ $76.00High
4/30/2020Canaccord GenuityLower Price TargetHold$66.00 ➝ $50.00High
4/30/2020UBS GroupLower Price TargetNeutral$70.00 ➝ $57.00Medium
4/29/2020Piper SandlerLower Price TargetOverweight$80.00 ➝ $65.00Low
3/24/2020Stifel NicolausLower Price TargetBuy$80.00 ➝ $40.00High
2/27/2020Berenberg BankReiterated RatingBuy$114.00High
2/27/2020Canaccord GenuityReiterated RatingHold$66.00High
11/25/2019Stifel NicolausBoost Price TargetBuy$80.00 ➝ $90.00High
11/20/2019Needham & Company LLCReiterated RatingBuy$88.00Low
10/30/2019Needham & Company LLCLower Price TargetBuy$91.00 ➝ $88.00Medium
9/9/2019Berenberg BankReiterated RatingBuy$114.00Low
9/6/2019Piper Jaffray CompaniesSet Price TargetBuy$90.00Low
9/6/2019Needham & Company LLCReiterated RatingBuy$91.00Medium
7/31/2019Needham & Company LLCSet Price TargetBuy$91.00Medium
7/31/2019Piper Jaffray CompaniesReiterated RatingBuyN/A
7/31/2019BTIG ResearchReiterated RatingHoldN/A
5/28/2019Needham & Company LLCReiterated RatingBuy$87.00Low
5/15/2019Needham & Company LLCReiterated RatingBuy$87.00Low
5/2/2019BTIG ResearchReiterated RatingHoldHigh
5/1/2019Piper Jaffray CompaniesLower Price TargetOverweight ➝ In-Line$120.00 ➝ $90.00High
4/9/2019Needham & Company LLCReiterated RatingBuy$100.00Low
4/5/2019Stifel NicolausReiterated RatingBuy$100.00Medium
4/2/2019UBS GroupBoost Price TargetNeutral$100.00 ➝ $105.00Low
3/5/2019BTIG ResearchReiterated RatingHoldLow
2/27/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$135.00 ➝ $120.00High
11/27/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$105.00High
11/21/2018BTIG ResearchReiterated RatingHoldLow
11/1/2018BTIG ResearchReiterated RatingHoldMedium
10/2/2018Jefferies Financial GroupBoost Price TargetBuy$150.00Low
9/17/2018Stifel NicolausBoost Price TargetBuy$135.00 ➝ $140.00Low
8/2/2018Stifel NicolausReiterated RatingBuy$135.00Medium
8/1/2018Needham & Company LLCReiterated RatingBuy$128.00 ➝ $135.00High
7/24/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$115.00 ➝ $130.00High
7/18/2018Needham & Company LLCReiterated RatingBuy$128.00Low
6/8/2018Stifel NicolausInitiated CoverageBuy$115.00Medium
5/31/2018Needham & Company LLCReiterated RatingBuy$102.00 ➝ $106.00High
5/3/2018BTIG ResearchReiterated RatingHoldLow
2/28/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$97.00 ➝ $104.00Low
2/27/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$76.00 ➝ $81.00Low
12/5/2017Canaccord GenuityReiterated RatingHold$76.00Low
12/5/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$93.00 ➝ $97.00Low
11/21/2017Needham & Company LLCBoost Price TargetBuy$93.00N/A
11/14/2017Canaccord GenuityReiterated RatingHold$76.00N/A
11/7/2017BTIG ResearchReiterated RatingHoldN/A
11/3/2017Piper Jaffray CompaniesReiterated RatingBuy$85.00N/A
11/3/2017Jefferies Financial GroupBoost Price TargetBuy$80.00 ➝ $91.00N/A
11/3/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$83.00 ➝ $89.00N/A
9/20/2017Canaccord GenuityReiterated RatingHold$71.00Low
9/15/2017Jefferies Financial GroupBoost Price TargetBuy$76.00 ➝ $80.00Low
9/15/2017Needham & Company LLCUpgradeHold ➝ Buy$83.00Low
9/14/2017Needham & Company LLCUpgradeHold ➝ Buy$83.00High
9/12/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$75.00Low
9/8/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$76.00High
8/23/2017Needham & Company LLCInitiated CoverageHold ➝ HoldLow
8/15/2017WBB SecuritiesDowngradeHold ➝ Sell$50.00Low
8/11/2017Berenberg BankReiterated RatingBuy$70.00Low
3/10/2017BTIG ResearchReiterated RatingHoldN/A
2/6/2017Canaccord GenuityReiterated RatingHold$54.00N/A
11/3/2016Canaccord GenuityLower Price TargetHold$67.00 ➝ $54.00N/A
8/31/2016WBB SecuritiesReiterated RatingHold$60.00N/A
8/5/2016Piper Jaffray CompaniesReiterated RatingOverweight$59.00 ➝ $70.00N/A
7/7/2016Piper Jaffray CompaniesReiterated RatingOverweight$61.00 ➝ $59.00N/A
(Data available from 6/21/2016 forward)
LivaNova logo
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $84.07
Low: $81.79
High: $84.48

50 Day Range

MA: $82.47
Low: $79.24
High: $86.34

52 Week Range

Now: $84.07
Low: $41.07
High: $90.25


235,933 shs

Average Volume

416,652 shs

Market Capitalization

$4.11 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of LivaNova?

The following Wall Street analysts have issued reports on LivaNova in the last year: Berenberg Bank, Needham & Company LLC, Piper Sandler, Robert W. Baird, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for LIVN.

What is the current price target for LivaNova?

4 Wall Street analysts have set twelve-month price targets for LivaNova in the last year. Their average twelve-month price target is $87.50, suggesting a possible upside of 6.4%. Robert W. Baird has the highest price target set, predicting LIVN will reach $100.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $68.00 for LivaNova in the next year.
View the latest price targets for LIVN.

What is the current consensus analyst rating for LivaNova?

LivaNova currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LIVN will outperform the market and that investors should add to their positions of LivaNova.
View the latest ratings for LIVN.

What other companies compete with LivaNova?

How do I contact LivaNova's investor relations team?

LivaNova's physical mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company's listed phone number is 44-0-20-3325-0660 and its investor relations email address is [email protected] The official website for LivaNova is